Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PETACC-6 in locally advanced rectal cancer
2006-006532-21Phase 3Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Apr 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in rectal cancer comparing Capecitabine + oxaliplatin with Capecitabine alone (2 arms). Primary endpoint: Disease-free survival. Started Apr 2008; status: completed.
02
Drugs
oxaliplatincapecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on 2006-006532-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006532-21.